Skip to Main Content

Paper Details

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Nat Commun
171
2020
+T-cells, CD8+, CD8+T, CD8+T-cells, PARP, PD, PD-1, PD-L1, PD-L1+macrophages, PD-L1+tumor cells, PD-L2, cancer, cancer cells, interferon, interferon-primed exhausted CD8, niraparib, ovarian cancer, patients, tumor, tumor samples
Author NameAffiliation
Huy NguyenDana-Farber Cancer Institute
Clarence YappHarvard Medical School
Sandro SantagataBrigham and Women's Hospital
Dipanjan ChowdhuryDana-Farber Cancer Institute
Dipanjan ChowdhuryDana-Farber Cancer Institute
Peter J ParkHarvard Medical School
Peter J ParkHarvard Medical School
Peter K SorgerHarvard Medical School
Alan D D'AndreaDana-Farber Cancer Institute
Alan D D'AndreaDana-Farber Cancer Institute
  • 1 - 10

Datasets

Release 1.2